Damora Therapeutics DMRA
NASDAQ DMRA
$21.53 +0.86 (+4.16%)
At close: Oct 21, 2026 · 4:00 PM EDT

Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026)

Updated

Damora Therapeutics' Other Non-Current Liabilities came in at $27,000 for Q2 2026, down 44.9% from $49,000 a year earlier and unchanged from the prior quarter.

Analysis

Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026) Analysis & Trends

At the end of FY2025, Damora Therapeutics' Other Non-Current Liabilities was $81,000, up 88.4% from FY2024.

  • Going back by year, Other Non-Current Liabilities was $43,000 in FY2024.
  • The five-year range for quarterly Other Non-Current Liabilities is $27,000 (Q1 2026) to $81,000 (Q4 2025).
  • Business Quant data shows DMRA's Other Non-Current Liabilities at $27,000 (Q1 2026), $81,000 (Q4 2025) and $49,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Damora Therapeutics 1.32 Bn -22.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 27,000.00
Mar 31, 2026 27,000.00
Dec 31, 2025 81,000.00
Sep 30, 2025 49,000.00
Jun 30, 2025 49,000.00
Mar 31, 2025 45,000.00
Dec 31, 2024 43,000.00
API Access

Damora Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=DMRA&period=max&api_key=YOUR_API_KEY